ClinicalTrials.gg
Sign In
Not yet recruitingNCT07482878Updated Jul 16, 2026

Tinder Fungus as an Adjunct to Non-surgical Periodontal Therapy for Periodontitis

An interventional study of Tinder fungus-based formulation and Commercially available toothpaste in Periodontitis, sponsored by Sigmund Freud PrivatUniversitat. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Sigmund Freud PrivatUniversitat · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.

The main questions it aims to answer is:

  • Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.

Participants will:

  • Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days
  • Visit the clinic at least twice including a visit before and after the intervention
  • Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.
02

Conditions studied

  • Periodontitis

Browse trials for

03

In context

Periodontitis

1,231 studies on the registry are indexed under Periodontitis; 295 are open to participants now.

This study's planned enrollment of 70 is above the median of 44 across 846 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Sigmund Freud PrivatUniversitat is the lead sponsor of 12 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Stage III or IV periodontitis
  • Patients who have not yet initiated periodontal therapy
  • Patients who have at least 20 remaining teeth
  • Patients who are willing to use an electric toothbrush
  • Patients who are willing to use interdental brushes

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received treatment for periodontitis
  • Patients who have already undergone or initiated periodontal therapy
  • Patients with a known allergy or intolerance to any component of the toothpaste or the powder
  • Patients who are already using a product that contains tinder fungus (Fomes fomentarius)
  • Patients who, at the time of periodontal treatment, are undergoing active systemic cancer therapy (e.g., chemotherapy or immunotherapy) or radiotherapy in the head and neck region, or for whom such therapy is planned. Previous illnesses or completed therapies do not constitute an exclusion criterion, provided that no current or planned treatment exists that could influence the periodontal treatment outcome or pose an increased risk for the participants.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Tinder fungus-based formulation (toothpaste and oral supplement powder)

    Tinder fungus toothpaste plus oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis

    Other: Tinder fungus-based formulation

  • Active comparator
    commercially available toothpaste

    Commercially available toothpaste as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis

    Other: Commercially available toothpaste

Interventions

  • OtherTinder fungus-based formulation

    Participants will receive Tinder fungus (Fomes fomentarius)-based formulations including a toothpaste plus an oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT).

  • OtherCommercially available toothpaste

    A standard commercially available toothpaste administered as an adjunct to NSPT.

06

What researchers measure

Primary outcomes

  1. Bleeding on probing (BoP in %) change

    Bleeding on probing (BoP in %) changes from baseline (T0) to reevaluation (T1). BOP will be recorded as yes/no for each of 6 sites and reported as the percentage of affected sites per participant.

    Time frame: changes from baseline (T0; 1 day before intervention starts) to reevaluation (T1; 5 weeks (±1 week) after intervention start)

07

Study locations

1 site
  • Dental Clinic of the Sigmund Freud Private University
    Vienna, State of Vienna 1020, Austria
    • Hady Haririan, Prof,Dr,PhD,MSc · Contacthady.haririan@med.sfu.ac.at · +4317201966
    • Brenda Laky, PD,MSc,PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 480 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 15 months is close to that.

Counting every sponsor, half of 494 studies reached it within 16 months; a quarter within 8 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 19, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482878
Lead sponsor
Sigmund Freud PrivatUniversitat
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Periodontitis →

Other studies from this sponsor

Sigmund Freud PrivatUniversitat

Start the discussion